Microarray big data integrated analysis to identify robust diagnostic signature for triple negative breast cancer

NoTriple negative breast cancers (TNBC) are clinically heterogeneous, an aggressive subtype with poor diagnosis and strong resistance to therapy. There is a need to identify novel robust biomarkers with high specificity for early detection and therapeutic intervention. Microarray gene expression-based studies have offered significant advances in molecular classification and identification of diagnostic/prognostic signatures, however sample scarcity and cohort heterogeneity remains area of concern. In this study, we performed integrated analysis on independent microarray big data studies and identified a robust 880-gene signature for TNBC diagnosis. We further identified 16-gene (OGN, ESR1, GPC3, LHFP, AGR3, LPAR1, LRRC17, TCEAL1, CIRBP, NTN4, TUBA1C, TMSB10, RPL27, RPS3A, RPS18, and NOSTRIN) that are associated to TNBC tissues. The 880-gene signature achieved excellent classification accuracy ratio on each independent expression data sets with overall average of 99.06%, is an indication of its diagnostic power. Gene ontology enrichment analysis of 880-gene signature shows that cell-cycle pathways/processes are important clinical targets for triple negative breast cancer. Further verification of 880-gene signature could provide additive knowledge for better understanding and future direction of triple negative breast cancer research